358570 - GI Innovation, Inc.

358570 Summary

Biopharma

Stock Price & Overview

₩8,090 +470 (+6.17%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩8,090 ≈ US$6 · Market cap ₩0.5tn (≈ $373m)

358570 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Revenue	5.8	0.0	5.3	3.5	5.6	11.0
Gross Profit	5.8	0.0	5.3	3.5	5.6	11.0
Operating Income	-40.7	-48.3	-53.3	-68.0	-30.6	-22.9
Finance Income	8.7	1.4	4.8	2.0	1.5	0.4
Finance Costs	2.9	4.4	0.7	4.2	102.0	46.7
Pretax Income	-35.1	-59.0	-55.0	-79.8	-150.7	-75.9
Income Tax Expense	0.0	-0.2	0.5	—	—	—
Net Income	-35.1	-58.8	-55.5	-79.8	-150.7	-75.9
Total Comprehensive Income	-34.9	-59.0	-55.9	-79.7	-150.6	-76.1

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	127.5	45.8	81.3	106.3	179.9	59.4
Current Assets	52.7	19.8	48.2	72.9	134.2	15.9
Cash & Cash Equivalents	39.7	1.0	8.5	2.3	1.9	6.2
Trade Receivables	—	—	—	0.0	0.1	0.0
Non-current Assets	74.8	25.9	33.1	33.5	45.7	43.5
Property, Plant & Equipment	9.5	6.1	8.6	11.4	11.5	7.6
Intangible Assets	1.7	1.5	1.6	1.5	1.6	0.5
Total Liabilities	11.0	16.7	9.6	10.7	9.4	171.8
Current Liabilities	9.3	4.7	5.8	6.6	5.2	169.0
Non-current Liabilities	1.7	12.0	3.8	4.1	4.2	2.8
Total Equity	116.5	29.1	71.7	95.6	170.4	-112.4
Share Capital	31.9	22.6	11.0	10.0	10.0	4.0
Retained Earnings	-326.4	-291.5	-432.5	-376.6	-296.9	-146.3

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Cash from Operating Activities	-32.3	-43.4	-41.2	-62.6	-26.6	-15.2
Cash from Investing Activities	-43.3	15.3	22.3	63.0	-139.2	-11.3
Purchase of Property, Plant & Equipment	7.4	0.0	0.6	2.9	3.8	3.2
Cash from Financing Activities	114.3	20.6	25.1	-0.0	161.5	31.4
Net Change in Cash	38.7	-7.6	6.2	0.4	-4.3	4.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	0.0	0.0	5.5	0.0	0.1	0.2	0.0	0.0	0.0	0.0
Gross Profit	0.0	0.0	5.5	0.0	0.1	0.2	0.0	0.0	0.0	0.0
Operating Income	-14.4	-12.4	-7.2	-10.7	-10.9	-11.8	-12.2	-13.8	-9.4	-12.9
Finance Income	0.7	0.7	5.2	2.0	1.2	0.2	0.3	0.4	0.3	0.4
Finance Costs	0.4	1.1	0.8	0.7	0.4	1.1	1.9	0.2	1.2	1.2
Pretax Income	-14.3	-12.3	-3.1	-9.5	-9.8	-12.8	-20.2	-14.2	-10.2	-14.4
Income Tax Expense	0.0	0.0	0.0	0.0	0.0	0.0	-0.2	0.0	—	0.0
Net Income	-14.3	-12.3	-3.1	-9.5	-9.8	-12.8	-20.0	-14.2	-10.2	-14.4
Total Comprehensive Income	-14.3	-12.3	-2.9	-9.5	-9.8	-12.8	-20.2	-14.2	-10.2	-14.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	105.5	116.1	127.5	129.1	136.9	144.5	45.8	64.8	56.5	66.8
Current Assets	48.4	33.7	52.7	52.4	61.0	123.2	19.8	31.8	27.3	36.3
Cash & Cash Equivalents	29.0	24.8	39.7	33.9	45.5	112.8	1.0	12.2	3.2	1.8
Non-current Assets	57.2	82.4	74.8	76.8	75.8	21.3	25.9	33.0	29.3	30.5
Property, Plant & Equipment	14.4	14.8	9.5	10.6	10.3	6.2	6.1	6.8	7.4	8.0
Intangible Assets	1.7	1.7	1.7	1.7	1.7	1.6	1.5	1.5	1.6	1.6
Total Liabilities	8.9	8.3	11.0	12.1	17.5	17.3	16.7	17.2	7.6	8.7
Current Liabilities	7.8	7.2	9.3	8.5	14.4	13.9	4.7	4.6	3.5	4.7
Non-current Liabilities	1.1	1.1	1.7	3.6	3.1	3.4	12.0	12.6	4.1	4.0
Total Equity	96.6	107.8	116.5	117.1	119.4	127.2	29.1	47.6	48.9	58.1
Share Capital	32.3	32.1	31.9	31.8	31.4	28.4	22.6	22.5	22.1	22.1
Retained Earnings	-353.1	-338.7	-326.4	-323.5	-314.1	-304.3	-291.5	-271.3	-257.1	-246.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-13.0	-10.9	-3.0	-9.2	-11.1	-9.0	-12.9	-10.8	-8.2	-11.6
Cash from Investing Activities	15.3	-5.1	6.9	-3.6	-57.7	11.1	1.0	-0.0	9.3	5.0
Purchase of Property, Plant & Equipment	0.1	6.4	1.5	0.4	4.8	0.7	0.0	0.0	0.0	0.0
Cash from Financing Activities	1.8	1.1	1.9	1.2	1.5	109.8	0.6	19.9	0.3	-0.2
Net Change in Cash	4.2	-14.8	5.8	-11.6	-67.4	111.8	-11.2	9.0	1.4	-6.8

Separate / parent-only (OFS) — this company files no consolidated statements, from DART. 6 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

358570 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	5.8	+23,943.4%	+18.6%	-11.9%	—
Operating income	-40.7	—	—	—	—
Net income	-35.1	—	—	—	—
EPS	₩-545	—	—	—	—
Operating cash flow	-32.3	—	—	—	—
Shareholders' equity	116.5	+301.0%	+6.8%	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

358570 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating margin	-696.4%	-198,751.9%	-1,002.2%	-1,941.5%	-547.0%	-207.6%
Net margin	-601.8%	-242,096.1%	-1,043.4%	-2,280.9%	-2,691.8%	-689.2%
Return on equity	-48.3%	-116.7%	-66.3%	-60.0%	-519.2%	—
Return on assets	-40.6%	-92.5%	-59.1%	-55.8%	-126.0%	-127.8%
Operating cash flow / revenue	-553.3%	-178,847.2%	-774.1%	-1,787.2%	-474.6%	-137.8%
Capex / revenue	126.3%	101.9%	10.6%	83.8%	68.4%	28.8%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 358570

Symbol	Last Price
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
317450Myungin Pharm	₩44,650 +0.0%
001060JW Pharmaceutical	₩27,500 +1.3%
456160G2GBIO, Inc.	₩37,950 +5.7%
019170Shinpoong Pharmaceutical Co., Ltd.	₩10,010 -0.9%
086900Medy-Tox, Inc.	₩69,600 +0.4%
397030April Bio Co., Ltd.	₩17,800 +6.1%
249420Ildong Pharm	₩15,030 -0.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.